Accueil   Diary - News   All news Poxel Closes a €26.5 Million Capital Increase

Poxel Closes a €26.5 Million Capital Increase

POXEL HOMEPOXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes (“Poxel”, or the “Company”), today announces the closing of a capital increase of 3,400,000 new ordinary shares without preferential subscription rights reserved for a category of investors for a total amount of €26.5 million.


Read the press release